Clinigen divests global rights to four cancer support therapies in support of move to solidify services.
In its continued efforts to increase the company’s focus on its pharmaceutical services market, Clinigen has divested four cancer supportive care products from its brands portfolio to CNX Therapeutics, a specialty pharmaceutical company. Those products, Cardioxane®, Savene®, Totect® and Ethyol®, address side effects patients may experience when treated with other cancer therapies. The financial terms for the divestment were not disclosed. Earlier this year, Clinigen sold Proleukin® to Iovance Biotherapeutics.
It also divested its European-based contract development business Lamda Laboratories SA, to Adragos Pharma GmbH. And late last year, Clinigen acquired Drug Safety Navigator, a specialist pharmacovigilance service provider based in the US.
The Clinigen services portfolio includes clinical trials sourcing, clinical supplies management, managed access and pharmacovigilance.
Jerome Charton, CEO of Clinigen, commented in a press release, “This divestment marks another milestone in Clinigen’s continued strategic evolution towards providing high-value services to the pharmaceutical and biotech sectors. These medicines have been integral to Clinigen, but as we refocus our efforts, it is crucial to align our offerings with our core strategy…”
Reference: “Clinigen divests global rights to four cancer support therapies to CNX Therapeutics,” 8/10/23. Clinigen press release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.